Similar divergent responses in cell viability and cell surface TRAIL death receptor levels were demonstrated for TRAIL (Keane et al, 1999; Srivastava, 2001; Jang et al, 2003; Song et al, 2003), and variations in sensitivity of glioma cell lines to an anti-TRAIL-R2 mAb were not correlated with TRAIL-R2 protein expression (Kaliberov et al, 2004). This evidence concerns the gene TNFSF10 and glioma.